Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Dalbavancin by AbbVie for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: Likelihood of Approval
Dalbavancin is under clinical development by AbbVie and currently in Phase III for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. According to...